Enhancing postmarketing surveillance: continuing challenges.
作者信息
French Dustin D, Margo Curtis E, Campbell Robert R
机构信息
Center for Healthcare Studies, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Veterans Affairs Health Services Research and Development, Chicago, IL, USA.
出版信息
Br J Clin Pharmacol. 2015 Oct;80(4):615-7. doi: 10.1111/bcp.12658. Epub 2015 Jun 1.
Abstract
摘要
相似文献
1
Enhancing postmarketing surveillance: continuing challenges.
Br J Clin Pharmacol. 2015 Oct;80(4):615-7. doi: 10.1111/bcp.12658. Epub 2015 Jun 1.
2
Postmarketing surveillance and reporting of adverse drug events.
S D J Med. 2004 Jan;57(1):13-4.
3
Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Pharmacogenomics. 2003 Sep;4(5):647-55. doi: 10.1517/phgs.4.5.647.23793.
4
Postmarketing surveillance-one of the key issues in drug development.
Ther Hung. 1992;40(4):147-53.
5
Reporting of adverse drug events: a key to postmarketing drug safety.
Am Fam Physician. 1992 Sep;46(3):873-4.
6
Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
Am J Ophthalmol. 2007 Jan;143(1):145-149. doi: 10.1016/j.ajo.2006.10.005. Epub 2006 Nov 13.
7
The demise of postmarketing surveillance.
Adverse Drug React Toxicol Rev. 1995 Spring;14(1):7-9.
8
Postmarketing surveillance: beyond MEDWatch.
JAMA. 1993 Nov 10;270(18):2180.
9
Xyrem (sodium oxybate) postmarketing adverse event reporting system.
Sleep Med. 2010 Jun;11(6):595; author reply 595-6. doi: 10.1016/j.sleep.2010.02.003. Epub 2010 Apr 1.
10
Postmarketing surveillance--lack of vigilance, lack of trust.
JAMA. 2004 Dec 1;292(21):2647-50. doi: 10.1001/jama.292.21.2647. Epub 2004 Nov 22.
引用本文的文献
1
Applying Machine Learning Techniques to Predict Drug-Related Side Effect: A Policy Brief.
Inquiry. 2025 Jan-Dec;62:469580251335805. doi: 10.1177/00469580251335805. Epub 2025 Jun 13.
2
Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada.
Ther Adv Drug Saf. 2019 Jul 26;10:2042098619865413. doi: 10.1177/2042098619865413. eCollection 2019.
本文引用的文献
1
Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Br J Clin Pharmacol. 2015 Oct;80(4):716-26. doi: 10.1111/bcp.12643. Epub 2015 May 28.
2
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
J Sex Med. 2015 Jan;12(1):139-51. doi: 10.1111/jsm.12726. Epub 2014 Oct 31.
3
Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy.
J Neuroophthalmol. 2015 Mar;35(1):12-5. doi: 10.1097/WNO.0000000000000186.
4
Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
Health Aff (Millwood). 2014 Aug;33(8):1453-9. doi: 10.1377/hlthaff.2014.0122.
5
Rooting out institutional corruption to manage inappropriate off-label drug use.
J Law Med Ethics. 2013 Fall;41(3):654-64. doi: 10.1111/jlme.12075.
6
Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers.
Drug Saf. 2008;31(3):241-7. doi: 10.2165/00002018-200831030-00005.
7
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Am J Ophthalmol. 2007 Mar;143(3):538-9. doi: 10.1016/j.ajo.2006.10.006. Epub 2006 Nov 13.
8
Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.
J Neuroophthalmol. 2005 Mar;25(1):9-13. doi: 10.1097/00041327-200503000-00003.
Zotero 插件